Cutaneous inflammation and proliferation in vitro: Differential effects and mode of action of topical glucocorticoids

Skin Pharmacology and Applied Skin Physiology

Volumn 13, Issue 2, 2000, Pages 93-103

  Lange, Katharina ^a   Kleuser, Burkhard ^a   Gysler, Anja ^a   Bader, Michael ^b   Maia, Claudia ^a   Scheidereit, Claus ^b   Korting, Hans Christian ^c   Schäfer Korting, Monika ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Benefit risk ratio; Fibroblasts; Giucocorticoid receptor subtypes; Interleukins; Keratinocytes; Topical glucocorticoids

Indexed keywords

17 ETHYLCARBONATE 21 PHENYLACETATE; ANTIINFLAMMATORY AGENT; BETAMETHASONE VALERATE; CYTOKINE; DESOXIMETASONE; DESOXIMETASONE 21 CINNAMATE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; PRODRUG; RECEPTOR SUBTYPE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA SYNTHESIS; DRUG DEGRADATION; DRUG METABOLISM; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; KERATINOCYTE; PRIORITY JOURNAL; RIBONUCLEASE PROTECTION ASSAY; RISK BENEFIT ANALYSIS; SKIN INFLAMMATION;

EID: 0034032378     PISSN: 14222868     EISSN: None     Source Type: Journal    
DOI: 10.1159/000029913     Document Type: Article

References (30)

1. Korting HC, Vieluf D. Kerscher M: 0.25% prednicarbate cream and the corresponding vehicle induce less skin atrophy than clobetasol 17-propionate cream. Eur J Clin Pharmacol 1992;42:159-161.
2. Dykes PJ, Hill S, Marks R: Assessment of the atrophogenic potential of corticosteroids by ultrasound and by epidermal biopsy under occlusive and nonocclusive conditions; in Christophers E, Schöpf E, Kligman AM, Stoughton RB (eds): Topical Corticosteroid Therapy. A Novel Approach to Safer Drugs. New York, Raven Press, 1988, pp 111-119.
3. Lange K, Gysler A, Kleuser B, Bader M, Korting HC, Schäfer-Korting M: Prednicarbate versus conventional topical glucocorticoids: Pharmacodynamic characterization in-vitro. Pharm Res 1997;14:1744-1749.
4. Schäfer-Korting M, Korting HC, Kerscher MJ, Lenhard S: Prednicarbate activity and benefit/risk-ratio in relation to other topical glucocorticoids. Clin Pharmacol Ther 1993; 54:448-456.
5. Schäfer-Korting M, Schmid MH, Korting HC: Topical glucocorticoids with improved benefit-risk ratio. Drug Safety 1996;14:375-385.
6. Kutsch CL, Norris DA, Arend WP: Tumor necrosis factor α induces interleukin-1α and interleukin-1 receptor antagonist production by cultured human keratinocytes. J Invest Dermatol 1993;101:79-85.
7. Goldring M, Goldring SR: Cytokines and cell growth control. Crit Rev Eukaryot Gene Expr 1991;1: 301-326.
8. Boxman ILA, Ruwhof C, Boerman OC, Löwik CWGM, Ponec M: Role of fibroblasts in the regulation of proinflammatory Il-1, Il-6 and Il-8 levels induced by keratinocyte derived Il-1. Arch Dermatol Res 1996; 288:391-398.
9. Kupper TS, Groves RW: The interleukin-1 axis and cutaneous inflammation. J Invest Dermatol 1995: 105:62S-66S.
10. Gysler A. Lange K, Korting HC, Schäter-Korting M: Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts. Pharm Res 1997;14:793-797.
11. Ray A, Prefontaine K: Physical association and functional antagonism between the p65 subunit of transcription factor NF-κB and the glucocorticoid receptor. Proc Natl Acad Sci USA 1994;91:752-756.
12. Scheinman RI, Cogswell PC, Lofquist AK. Baldwin AS: Role of transcriptional activation of IκBα in mediation of immunsuppression by glucocorticoids. Science 1995;270: 283-286.
13. Klein-Hitpass L, Schwerk C, Kahmann S: Targets of activated steroid hormone receptors: Basal transcription factors and receptor interacting proteins. J Mol Med 1998;76:490-496.
14. Göttlicher M, Heck S, Herrlich P: Transcriptional cross-talk, the second mode of steroid hormone receptor action. J Mol Med 1998;76:480-489.
15. Nishida T, Nishino N, Takano M, Kawai K, Bando K, Masui Y, Nakai S, Hirai Y: cDNA cloning of II-1α and II-1β from mRNA of U 937 cell line. Biochem Biophys Res Commun 1987;143:345-352.
16. Wong H, Anderson WD, Cheng T, Riabowol KT: Monitoring mRNA expression by polymerase chain reaction: The 'primer-dropping' method. Anal Biochem 1994;223: 251-258.
17. Tso JY, Sun XH, Kao TH, Reece KS, Wu R: Isolation and characterization of rat and human glyceralde-hyde-3-phosphate dehydrogenase cDNAs: Genomic complexity and molecular evolution of the gene. Nucl Acids Res 1985;13:2485-2502.
18. Kawakami K, Scheidereit C, Roeder RG: Identification and purification of a human immunoglobulin-en-hancer-binding protein (NFκB) that activates transcription from human immunodeficiency virus typ 1 promoter in vitro. Proc Natl Acad Sci USA 1988;85:4700-4704.
19. Sambrook J, Fritsch EF, Maniatis T (eds): Molecular Cloning. Cold Spring Harbor, Cold Spring Harbor Laboratory Press, 1989, p 5.40.
20. Naumann M, Wulczyn C, Scheidereit C: The NF-κB precursor and the protooncogene product Bcl-3 are IκB molecules and control nuclear translocation of NF-κB. EMBO J 1993;12:213-222.
21. Pagé M, Bejaoui N, Cinq-Mars B, Lemieux P: Optimization of the tetrazolium-based colorimetric assay for the measurement of the cell number and cytotoxicity. J Immun Pharmacol 1988;10:785-793.
22. Bjerring P: Comparison of the bioactivity of mometasone furoate 0.1% fatty cream, betamethasone dipropionate 0.05% cream and betamethasone valerate 0.1% cream in humans. Skin Pharmacol 1993;6: 187-192.
23. Isogai M, Shimizu H, Yoshio E, Terasawa T, Okada T, Sugeno K: Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue. J Steroid Biochem Biol 1993;44:141-145.
24. Barton EB, Jakway JP, Smith SR, Siegel MI: Cytokine inhibition by a novel steroid mometasone furoate. Immunopharmacol Immunotoxicol 1991;13:251-261.
25. Niedner R, Schöpf E: Clinical efficacy of topical glucocorticoid preparations and other types of dermatics in inflammatory skin diseases, particularly in atopic dermatitis; in Korting HC, Maibach HI (eds): Topical Glucocorticoids with Increased Benefit/ Risk-Ratio. Basel, Karger, 1993, pp 157-169.
26. Aliaga A, Rodriguez M, Armijo M, Bravo J, López Avila A, Mascaro JM, Ferrando J, Del Rio R, Lozano R, Balaguer A: A double blind study of prednicarbate versus fluocortin butyl ester in atopic dermatitis. Int J Dermatol 1996;35:131-132.
27. Würthwein G, Rehder S, Rhodewald P: Lipophilicity and receptor affinity of glucocorticoids. Pharm Zeitung Wiss 1992;4:161-166.
28. Bamberger ChM, Bamberger AM, DeCastro M, Chrousos GP: Glucocorticoidreceptor β, a potential endogenous inhibitor of glucocorticoid actions in humans. J Clin Invest 1995;95:2435-2441.
29. Bamberger ChM, Bamberger AM, Wald M, Chrousos GP, Schulte HM: Inhibition of mineral corticoid activity by the beta-isoform of the human glucocorticoid receptor. J Steroid Biochem Mol Biol 1997;60: 43-50.
30. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M: Immunosuppression by glucocorticoids: Inhibition of NFκB activity through induction of IκB synthesis. Science 1995;270:286-290.